

**Appl. No.** : **10/032,996**  
**Filed** : **December 27, 2001**

### **AMENDMENTS TO THE CLAIMS**

Claim 1 – 26 (Canceled).

22. (Canceled).

23. (Canceled).

24. (Canceled).

25. (Canceled).

26. (Canceled).

27. (Previously presented) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7),

lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

28. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7).

29. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.

30. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7).

31. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide..

Appl. No. : 10/032,996  
Filed : December 27, 2001

32. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

33. (Currently amended) A chimeric polypeptide comprising a polypeptide according to Claim 22 27 fused to a heterologous polypeptide.

34. (Previously presented) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

35. (New) An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said isolated polypeptide retains the biological activity of a native PRO539 polypeptide.

36. (New) The isolated polypeptide of Claim 35, wherein any substitution in the amino acid sequence of said isolated polypeptide is a conservative substitution.

37. (New) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 96%.

38. (New) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 97%.

39. (New) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 98%.

40. (New) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 99%.

41. (New) An isolated polypeptide having at least 95% amino acid sequence identity to:

**Appl. No.** : 10/032,996  
**Filed** : December 27, 2001

- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein any substitution in the amino acid sequence of said isolated polypeptide is a conservative substitution.

42. (New) The isolated polypeptide of Claim 41, wherein said amino acid sequence identity is at least 96%.

43. (New) The isolated polypeptide of Claim 41, wherein said amino acid sequence identity is at least 97%.

44. (New) The isolated polypeptide of Claim 41, wherein said amino acid sequence identity is at least 98%.

45. (New) The isolated polypeptide of Claim 41, wherein said amino acid sequence identity is at least 99%.

Appl. No. : 10/032,996  
Filed : December 27, 2001

CONCLUSION

Applicants have included the entire claim set in the listing of the claims to comply with the requirements of 37 CFR §1.121, as amended on June 30, 2003. Applicants invite the Examiner to call the undersigned if any remaining issues may be resolved by telephone.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 30, 2004

By:

  
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550

S:\DOCS\BSG\BSG-1332.DOC  
072804